Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastrointestinal Stromal Tumors: early-phase trial registry
4 of 12 indexed Gastrointestinal Stromal Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 4 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Gastrointestinal Stromal Tumors: 12 US clinical trials tracked, 4 recruiting.
Gastrointestinal Stromal Tumors is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition gastrointestinal-stromal-tumors
OPEN 4 | RECR 33% | LATE 2 | EARLY 9 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Gastrointestinal Stromal Tumors lists 4 open slots (33% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastrointestinal Stromal Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastrointestinal Stromal Tumors is recruiting below its size-band peers.
4 of 12 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastrointestinal Stromal Tumors research.
Novartis Pharmaceuticals accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Gastrointestinal Stromal Tumors trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
Gastrointestinal Stromal Tumors research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
NCT05366816
Imatinib TDM in GIST
Reema A. Patel
NCT05493215
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Deciphera Pharmaceuticals
NCT03673501
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Sarcoma Alliance for Research through Collaboration
NCT06208748
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Adam Burgoyne, MD, PhD
NCT03556384
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
NCT06087263
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Bayer
NCT01271712
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis Pharmaceuticals
NCT00135005
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
Exelixis
NCT00570635
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis Pharmaceuticals
NCT00441155
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastrointestinal Stromal Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastrointestinal Stromal Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastrointestinal Stromal Tumors page
12 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Gastrointestinal Stromal Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Gastrointestinal Stromal Tumors trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Stromal Tumors condition card totals 12 registered trials; most-linked intervention Regorafenib; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.